Advanced Androgen Blockage in Nonmetastatic Castration-resistant Prostate Cancer: An Indirect Comparison of Apalutamide and Enzalutamide

Christopher J.D. Wallis, Thenappan Chandrasekar, Hanan Goldberg, Laurence Klotz, Neil Fleshner, Raj Satkunasivam, Zachary W A Klaassen

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) have historically had few treatment options. Recently, randomized controlled trials have examined the benefit of apalutamide and enzalutamide in these patients. We sought to perform an indirect treatment comparison using a network meta-analysis approach to compare the relative efficacy and toxicity of these two agents. The primary outcome of this analysis was metastasis-free survival (MFS) while secondary outcomes were time to prostate-specific antigen progression, overall survival, and adverse events. The Bucher technique for indirect comparison was used to compare apalutamide and enzalutamide using the common placebo comparator. We found no evidence of a significant difference in MFS (hazard ratio 1.04, 95% confidence interval 0.78–1.37) between enzalutamide and apalutamide. Similarly, there were no differences for any of the secondary outcomes. While indirect comparisons cannot supplant direct comparative data, this analysis suggests that apalutamide and enzalutamide are similarly effective in delaying metastases for patients with nmCRPC. Patient summary: Historically, there have been few treatment options for prostate cancer patients receiving androgen deprivation therapy who have rising prostate-specific antigen levels without obvious recurrence of cancer. Recent randomized controlled trials demonstrated that treatment with enzalutamide and apalutamide delayed the development of metastatic cancer. This study demonstrates through an indirect comparison that both medications are likely to have similar efficacy and side-effect profiles. Recent data support the use of apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer. This analysis demonstrates no significant differences in efficacy and toxicity between these two agents.

Original languageEnglish (US)
Pages (from-to)238-241
Number of pages4
JournalEuropean Urology Oncology
Volume1
Issue number3
DOIs
StatePublished - Aug 1 2018
Externally publishedYes

Fingerprint

Castration
Androgens
Prostatic Neoplasms
Prostate-Specific Antigen
Neoplasm Metastasis
Survival
Randomized Controlled Trials
Therapeutics
MDV 3100
Neoplasms
Placebos
Confidence Intervals
Recurrence

Keywords

  • Androgen deprivation therapy
  • Apalutamide
  • Castration-resistant prostate cancer
  • Enzalutamide
  • Locally advanced prostate cancer

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Surgery
  • Oncology
  • Urology

Cite this

Advanced Androgen Blockage in Nonmetastatic Castration-resistant Prostate Cancer : An Indirect Comparison of Apalutamide and Enzalutamide. / Wallis, Christopher J.D.; Chandrasekar, Thenappan; Goldberg, Hanan; Klotz, Laurence; Fleshner, Neil; Satkunasivam, Raj; Klaassen, Zachary W A.

In: European Urology Oncology, Vol. 1, No. 3, 01.08.2018, p. 238-241.

Research output: Contribution to journalArticle

Wallis, Christopher J.D. ; Chandrasekar, Thenappan ; Goldberg, Hanan ; Klotz, Laurence ; Fleshner, Neil ; Satkunasivam, Raj ; Klaassen, Zachary W A. / Advanced Androgen Blockage in Nonmetastatic Castration-resistant Prostate Cancer : An Indirect Comparison of Apalutamide and Enzalutamide. In: European Urology Oncology. 2018 ; Vol. 1, No. 3. pp. 238-241.
@article{ea49f066c7524dddb336eee7fc613846,
title = "Advanced Androgen Blockage in Nonmetastatic Castration-resistant Prostate Cancer: An Indirect Comparison of Apalutamide and Enzalutamide",
abstract = "Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) have historically had few treatment options. Recently, randomized controlled trials have examined the benefit of apalutamide and enzalutamide in these patients. We sought to perform an indirect treatment comparison using a network meta-analysis approach to compare the relative efficacy and toxicity of these two agents. The primary outcome of this analysis was metastasis-free survival (MFS) while secondary outcomes were time to prostate-specific antigen progression, overall survival, and adverse events. The Bucher technique for indirect comparison was used to compare apalutamide and enzalutamide using the common placebo comparator. We found no evidence of a significant difference in MFS (hazard ratio 1.04, 95{\%} confidence interval 0.78–1.37) between enzalutamide and apalutamide. Similarly, there were no differences for any of the secondary outcomes. While indirect comparisons cannot supplant direct comparative data, this analysis suggests that apalutamide and enzalutamide are similarly effective in delaying metastases for patients with nmCRPC. Patient summary: Historically, there have been few treatment options for prostate cancer patients receiving androgen deprivation therapy who have rising prostate-specific antigen levels without obvious recurrence of cancer. Recent randomized controlled trials demonstrated that treatment with enzalutamide and apalutamide delayed the development of metastatic cancer. This study demonstrates through an indirect comparison that both medications are likely to have similar efficacy and side-effect profiles. Recent data support the use of apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer. This analysis demonstrates no significant differences in efficacy and toxicity between these two agents.",
keywords = "Androgen deprivation therapy, Apalutamide, Castration-resistant prostate cancer, Enzalutamide, Locally advanced prostate cancer",
author = "Wallis, {Christopher J.D.} and Thenappan Chandrasekar and Hanan Goldberg and Laurence Klotz and Neil Fleshner and Raj Satkunasivam and Klaassen, {Zachary W A}",
year = "2018",
month = "8",
day = "1",
doi = "10.1016/j.euo.2018.04.004",
language = "English (US)",
volume = "1",
pages = "238--241",
journal = "European urology oncology",
issn = "2588-9311",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - Advanced Androgen Blockage in Nonmetastatic Castration-resistant Prostate Cancer

T2 - An Indirect Comparison of Apalutamide and Enzalutamide

AU - Wallis, Christopher J.D.

AU - Chandrasekar, Thenappan

AU - Goldberg, Hanan

AU - Klotz, Laurence

AU - Fleshner, Neil

AU - Satkunasivam, Raj

AU - Klaassen, Zachary W A

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) have historically had few treatment options. Recently, randomized controlled trials have examined the benefit of apalutamide and enzalutamide in these patients. We sought to perform an indirect treatment comparison using a network meta-analysis approach to compare the relative efficacy and toxicity of these two agents. The primary outcome of this analysis was metastasis-free survival (MFS) while secondary outcomes were time to prostate-specific antigen progression, overall survival, and adverse events. The Bucher technique for indirect comparison was used to compare apalutamide and enzalutamide using the common placebo comparator. We found no evidence of a significant difference in MFS (hazard ratio 1.04, 95% confidence interval 0.78–1.37) between enzalutamide and apalutamide. Similarly, there were no differences for any of the secondary outcomes. While indirect comparisons cannot supplant direct comparative data, this analysis suggests that apalutamide and enzalutamide are similarly effective in delaying metastases for patients with nmCRPC. Patient summary: Historically, there have been few treatment options for prostate cancer patients receiving androgen deprivation therapy who have rising prostate-specific antigen levels without obvious recurrence of cancer. Recent randomized controlled trials demonstrated that treatment with enzalutamide and apalutamide delayed the development of metastatic cancer. This study demonstrates through an indirect comparison that both medications are likely to have similar efficacy and side-effect profiles. Recent data support the use of apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer. This analysis demonstrates no significant differences in efficacy and toxicity between these two agents.

AB - Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) have historically had few treatment options. Recently, randomized controlled trials have examined the benefit of apalutamide and enzalutamide in these patients. We sought to perform an indirect treatment comparison using a network meta-analysis approach to compare the relative efficacy and toxicity of these two agents. The primary outcome of this analysis was metastasis-free survival (MFS) while secondary outcomes were time to prostate-specific antigen progression, overall survival, and adverse events. The Bucher technique for indirect comparison was used to compare apalutamide and enzalutamide using the common placebo comparator. We found no evidence of a significant difference in MFS (hazard ratio 1.04, 95% confidence interval 0.78–1.37) between enzalutamide and apalutamide. Similarly, there were no differences for any of the secondary outcomes. While indirect comparisons cannot supplant direct comparative data, this analysis suggests that apalutamide and enzalutamide are similarly effective in delaying metastases for patients with nmCRPC. Patient summary: Historically, there have been few treatment options for prostate cancer patients receiving androgen deprivation therapy who have rising prostate-specific antigen levels without obvious recurrence of cancer. Recent randomized controlled trials demonstrated that treatment with enzalutamide and apalutamide delayed the development of metastatic cancer. This study demonstrates through an indirect comparison that both medications are likely to have similar efficacy and side-effect profiles. Recent data support the use of apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer. This analysis demonstrates no significant differences in efficacy and toxicity between these two agents.

KW - Androgen deprivation therapy

KW - Apalutamide

KW - Castration-resistant prostate cancer

KW - Enzalutamide

KW - Locally advanced prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85057861920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057861920&partnerID=8YFLogxK

U2 - 10.1016/j.euo.2018.04.004

DO - 10.1016/j.euo.2018.04.004

M3 - Article

C2 - 31102627

AN - SCOPUS:85057861920

VL - 1

SP - 238

EP - 241

JO - European urology oncology

JF - European urology oncology

SN - 2588-9311

IS - 3

ER -